Residual Scope: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia AALL1521

Pharmacology, Toxicology and Pharmaceutical Science

1. Janus Kinase 2 Inhibitor 100%
2. Acute Lymphoblastic Leukemia 100%
3. Ruxolitinib 100%
4. Janus Kinase 1 100%
5. Chemotherapy Regimens 100%
6. Polycythemia vera 50%
7. Growth Factor 16%
8. Myeloproliferative Neoplasm 16%
9. Malignant Neoplasm 16%
10. Cytokine Receptor 16%
11. Protein Tyrosine Kinase 16%
12. Cytokine 16%
13. Janus Kinase 16%
14. Diseases 16%